Company Overview and News

 
AET / Aetna, Inc. null

2018-10-16 sec.gov
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"[email protected],"!O8FH-/#PO3&EN96%R:7IE9" [email protected],S,V M,CDO3R Q,2]%(#(X,[email protected],B]4(#,S,S,[email protected]@6R [email protected],30Y73X^#65N M9&]B:@[email protected](" @(" @(" @(" @(" @(" @#0HQ-B P(&]B:@T\/"]$96-O9&50 M87)M7!E+UA2968O5ULQ(#(@,5T^/G-T('[email protected]&)D:&&2 E#(Q,_QEW_P<(, "[email protected][email protected] M#0IE;F1S=')E86T-96YD;V)J#7-T87)T>')[email protected]*, T*)25%3T8-"B @(" @ M(" @#0HQ.2 P(&]B:@T\/"]&:6QT97(O1FQA=&5$96-O9&4O22 X,R],96YG [email protected]@-S O4R T.
AET

 
AET / Aetna, Inc. null

2018-10-16 sec.gov
Document
AET

 
AET / Aetna, Inc. null

2018-10-16 sec.gov
begin 644 filename1.pdf M)5!$1BTQ+C4*)>+CS],*,2 P(&]B:@H\/"]4>7!E+UA/8FIE8W0O0V]L;W)3 M<&%C92]$979I8V5'
AET

 
AET / Aetna, Inc. null

2018-10-16 sec.gov
Document AET

 
AET / Aetna, Inc. null

2018-10-16 sec.gov
Document
AET

 
AET / Aetna, Inc. null

2018-10-16 sec.gov
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"[email protected],"!O8FH-/#PO3&EN96%R:7IE9" [email protected],S0Q M.3,O3R Q,2]%(#(X,S [email protected],B]4(#,S.#[email protected]@6R [email protected],30Y73X^#65N M9&]B:@[email protected](" @(" @(" @(" @(" @(" @#0HQ-B P(&]B:@T\/"]$96-O9&50 M87)M7!E+UA2968O5ULQ(#(@,5T^/G-T('$UQX&)D:&&2 E#(Q,_QEW_P<(, "0Z [email protected] M#0IE;F1S=')E86T-96YD;V)J#7-T87)T>')[email protected]*, T*)25%3T8-"B @(" @ M(" @#0HQ.2 P(&]B:@T\/"]&:6QT97(O1FQA=&5$96-O9&4O22 X,R],96YG [email protected]@-S O4R T.
AET

 
AET / Aetna, Inc. null

2018-10-16 sec.gov
Document AET

 
AET / Aetna, Inc. null

2018-10-16 sec.gov
Document
AET

 
AET / Aetna, Inc. null

2018-10-16 sec.gov
begin 644 filename1.pdf M)5!$1BTQ+C4*)>+CS],*,2 P(&]B:@H\/"]4>7!E+UA/8FIE8W0O0V]L;W)3 M<&%C92]$979I8V5'
AET

5
UnitedHealth's (UNH) Q3 Earnings Beat, 2018 Guidance Raised

2018-10-16 zacks
UnitedHealth Group Inc.’s (UNH - Free Report) third-quarter 2018 earnings of $3.41 per share surpassed the Zacks Consensus Estimate by 3.33%. The same was up 28% year over year.
MOH CTRL AET UNH THC

10
Merger Arbitrage Mondays - October 15, 2018

2018-10-16 seekingalpha
Aetna and CVS Health Corporation entered into a consent decree with the United States Department of Justice.
CALL CVS COL AET

25
Brunch, Craft Beer & Investing: Embracing Volatility & Managing Risk

2018-10-16 seekingalpha
Welcome to the Brunch, Craft Beer, and Investing Portfolio Review. If you've been here before, you know the holdings have nothing to do with brunch or craft beer. These are just hobbies of mine. My last portfolio review will give you a brief overview of the portfolio's origins, goals, and evolving strategy. Per usual, the strategy continues to evolve.
FB ALB WLK CMCSA THO LACDF FDX SWKS V MTN EMN AAPL SSTI MSFT OROCF AET LAC

18
UPDATE 1-UnitedHealth tops earnings estimates, raises 2018 forecast

2018-10-16 reuters
(Reuters) - UnitedHealth Group Inc added more members to its health plans in the third quarter, helping it to post a profit well above Wall Street estimates and boost its earnings forecast for the year.
CI CVS AET UNH

49
In a Cold Market, Walmart Stock Is Hot

2018-10-15 investorplace
As the stock market has cooled in October, the stability of Walmart (NYSE:WMT) has made it a hot stock. The rally began in August after the company reported 4.5% growth in U.S. year-over-year sales . Since then, the shares are up about 8%, while the average Nasdaq stock is down 4%.
DB AMZN PYPL AXP CVS HUM AET WMT

9
Will Optum Aid UnitedHealth Group's (UNH) Q3 Earnings?

2018-10-15 zacks
In the third quarter, we expect earnings growth at UnitedHealth Group Inc.’s (UNH - Free Report) health services business Optum. Increased revenues and earnings from operations should accrue from better productivity and overall cost management initiatives.
LMT MOH CI AET UNH

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to AET / Aetna, Inc. on message board site Silicon Investor.

Aeterna Zentaris (AEZS) Aeterna Zentaris (AEZS) Aeterna Zentaris (AEZS) AEterna Zentaris (NASDAQ: AEZS) AEterna Zentaris (NASDAQ: AEZS) AEterna Zentaris (NASDAQ: AEZS)
Aethlon Medical BSEQ Aethlon Medical BSEQ Aethlon Medical BSEQ Aetna, Inc. (AET) Aetna, Inc. (AET) Aetna, Inc. (AET)
AETC: Applied Extrusion Tech. AETC: Applied Extrusion Tech. AETC: Applied Extrusion Tech. Aeterna (M.AEL) Aeterna (M.AEL) Aeterna (M.AEL)
Aetna ( aet) Aetna ( aet) Aetna ( aet) AETG - American Entertainment Group - Up on Volume AETG - American Entertainment Group - Up on Volume AETG - American Entertainment Group - Up on Volume
Advanced Encryption Technology (AETI) Goes Public w/a Bang Advanced Encryption Technology (AETI) Goes Public w/a Bang Advanced Encryption Technology (AETI) Goes Public w/a Bang AETI announces acquisition of Metisse Information Systems AETI announces acquisition of Metisse Information Systems AETI announces acquisition of Metisse Information Systems
CUSIP: 00817Y108